

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CK Life Sciences Int'l. (Holdings) Inc.

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

BUSINESS UPDATE ON PRECLINICAL STUDIES OF CANCER VACCINES

CK Life Sciences Int'l. (Holdings) Inc. (the “Company”) announces that Sequencio Therapeutics Company Limited (“Sequencio”), a subsidiary of the Company will present data from its therapeutic cancer vaccine research pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, USA.

Five research abstract presentations will highlight data from preclinical studies of investigational cancer vaccines targeting p53 neoantigen, IGF1R (insulin-like growth factor 1 receptor), B7-H3 (B7 homolog 3), TROP2 (trophoblast cell surface antigen 2) and Claudin 6 respectively.

These presentations mark Sequencio’s first major scientific unveiling since its formation and showcase significant advancements in next-generation cancer vaccine technologies based on Sequencio’s proprietary TrueHLA™ Epitope-to-Efficacy™ translational design framework, which enables rational, data-driven vaccine development across circRNA, mRNA, peptide, and protein-based platforms.

Collectively, these presentations highlight a consistent theme: rationally designed cancer vaccines that demonstrate robust immunogenicity and compelling anti-tumour activity across multiple targets and modalities in preclinical models. The data presented in these presentations underscore the strength of Sequencio’s approach to translating antigen selection into functional immune responses and tumour control. Building on this foundation, Sequencio is prioritising its most promising programs for IND-enabling studies, with the goal of accelerating select vaccine candidates into early-stage clinical development through strategic partnerships and global collaboration.

It should be noted that the research is only at the preclinical stage and the Company has not yet commenced clinical trials for these vaccines and accordingly, there is no assurance of the outcome. Shareholders of the Company and potential investors are therefore advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
CK Life Sciences Int'l. (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 31 March 2026

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel, Mr. Lance Richard Lee Yuen and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).